ReviewProstate cancer and prostatic diseases2010
Urine markers in monitoring for prostate cancer.
Review in Prostate cancer and prostatic diseases, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Machine learning-based MRI imaging for prostate cancer diagnosis: systematic review and meta-analysis.Prostate cancer and prostatic diseases · 2026Pooled it
- Prostate cancer biomarkers: from early diagnosis to precision treatment.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Review
- Prostate Cancer Microvascular Routes: Exploration and Measurement Strategies.Life (Basel, Switzerland) · 2023Review
- Nurturing the marriages of urinary liquid biopsies and nano-diagnostics for precision urinalysis of prostate cancer.Smart medicine · 2023Review
- Copy number variation of urine exfoliated cells by low-coverage whole genome sequencing for diagnosis of prostate adenocarcinoma: a prospective cohort study.BMC medical genomics · 2022Article
- Curzerene suppresses progression of human glioblastoma through inhibition of glutathione S-transferase A4.CNS neuroscience & therapeutics · 2022Article
- Prostate cancer-associated urinary proteomes differ before and after prostatectomy.Therapeutic advances in medical oncology · 2022Article
- Non-invasive Urine Test for Molecular Classification of Clinical Significance in Newly Diagnosed Prostate Cancer Patients.Frontiers in medicine · 2021Article
- Development and validation of a 25-Gene Panel urine test for prostate cancer diagnosis and potential treatment follow-up.BMC medicine · 2020Article
- Angiogenesis Inhibition in Prostate Cancer: An Update.Cancers · 2020Review
- Establishing a Urine-Based Biomarker Assay for Prostate Cancer Risk Stratification.Frontiers in cell and developmental biology · 2020Article
- PLCε knockdown prevents serine/glycine metabolism and proliferation of prostate cancer by suppressing YAP.American journal of cancer research · 2020Article
- Glycans as Biomarkers in Prostate Cancer.International journal of molecular sciences · 2019Review
- Article
- Evaluation of VEGF and PEDF in prostate cancer: A preliminary study in serum and biopsies.Oncology letters · 2018Article
- Development of sarcosine quantification in urine based on enzyme-coupled colorimetric method for prostate cancer diagnosis.EXCLI journal · 2018Article
- Use of two gene panels for prostate cancer diagnosis and patient risk stratification.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- Urinary microRNA-based signature improves accuracy of detection of clinically relevant prostate cancer within the prostate-specific antigen grey zone.Molecular medicine reports · 2016Article
- Urinary Polyamines: A Pilot Study on Their Roles as Prostate Cancer Detection Biomarkers.PloS one · 2016Article
- Novel non-invasive biomarkers that distinguish between benign prostate hyperplasia and prostate cancer.BMC cancer · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The major advantages of urine-based assays are their noninvasive character and ability to monitor prostate cancer with heterogeneous foci. Almost all urine-detectable prostate-specific markers have been recently reviewed. For this reason, we focus here on only a few promising markers which have been independently evaluated (in particular PCA3, fusion genes, TERT, AMACR, GSTP1, MMP9 and VEGF) and very recent ones (ANXA3 and sarcosine). The emphasis is also on multiplex biomarker analysis and on microarray-based analysis of fusion genes. A combination of multiple urine biomarkers may be valuable in the case of men with persistently elevated serum prostate-specific antigen and a history of negative biopsies. The emerging urine tests should help in both early diagnosis of prostate cancer and identifying aggressive tumors for radical treatment.
Indexed as
Identifiers
19652665What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.